A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. - Test2 - elhamkhani - TriplyDB

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.

http://www.wikidata.org/entity/Q39004366

about

Bispecific antibodies and their applications The roles of stem cell memory T cells in hematological malignancies Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia CCR9 in cancer: oncogenic role and therapeutic targeting Second-generation inhibitors of Bruton tyrosine kinase Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.An update on current and prospective immunotherapies for chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide.Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma

P2860

Q26774024-C124A24D-D297-4437-9227-5771C8F1CED7 Q26783681-6639BC5C-97D7-426B-90A6-9F8596D519C0 Q26785828-8B88CD1F-95CC-43C2-A51E-108F40E3E71A Q28066712-835088AE-CCC1-48B1-9F82-9DE0DB967203 Q28076118-0E36823F-3739-48B8-8CF4-34C3016A51AF Q34440110-CC2EDB88-D786-4772-ABF9-9421530E7767 Q36131489-6A80A8B5-701D-4BE0-AA2F-21433B98CBAB Q38445357-3C63B069-F86F-496D-BD0B-97B927321304 Q38543771-99EA4F59-0583-4053-BDD1-2A6DB4E9B0EF Q38640917-143FACB6-66AA-4343-BB54-B12E5D51A168 Q38989496-A52B1A40-29E1-46F9-9D70-D6C2670F5A79 Q40575818-0F65C33F-3092-4093-97EC-F94A1834EA29 Q42209070-F17703B8-AA01-4DD9-817D-B9F0E499B393 Q55312558-8A61FFCD-7D0E-4F3F-87A1-97FA9563611B Q56889030-C1580318-9102-4F1A-B83A-59CBD6D89CBD

P2860

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.

http://www.wikidata.org/entity/Q39004366

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

A novel anti-CD19 monoclonal a ...... y against B cell malignancies.

@en

A novel anti-CD19 monoclonal antibody

@nl

type

label

A novel anti-CD19 monoclonal a ...... y against B cell malignancies.

@en

A novel anti-CD19 monoclonal antibody

@nl

prefLabel

A novel anti-CD19 monoclonal a ...... y against B cell malignancies.

@en

A novel anti-CD19 monoclonal antibody

@nl

P1433

Q39004366-65A9310E-BBF2-40DE-AB64-95145A60AEE1

P1476

Q39004366-95C8338F-3311-4A59-9902-DC7790299D7B

P2093

Q39004366-48038A6E-6D47-4C0F-AE1F-C68FCF28ED02

Q39004366-5D7D4123-FDA5-4709-9B7F-BECCBEB0EC3C

Q39004366-AC4563BC-6099-45E3-8A5A-72E79AF7B282

Q39004366-ADE26FB3-677B-44F0-ABE6-972C2A598DE9

Q39004366-B6211707-07F2-439F-AEE9-34F816B3663B

Q39004366-B6B2B289-CB73-46D6-BBFF-329BE2FF6F0A

Q39004366-CFC59D45-D189-413D-A966-DFF9CFE584FF

Q39004366-D7F56CD4-1825-4B41-8905-239FD1EF8E6D

P2860

Q39004366-02836AEB-C158-4A14-9B55-B4DA5A7E1D2A

Q39004366-143F8174-5046-4735-A5BF-4F6151DB9449

Q39004366-17BA529B-C093-4752-9BED-EA4DCD41A261

Q39004366-1931FC42-D182-4A32-BC5D-484A84BB8F5A

Q39004366-1D9C7A20-382F-462F-B1AB-F9BB20E6E84A

Q39004366-1DC0551C-F469-4719-9638-00D107227890

Q39004366-227B35DD-4648-4024-9A6C-1E87C22B704A

Q39004366-2B1F558B-3115-4339-8E3E-996B6D61B49E

Q39004366-2B351323-434C-4806-951B-665226CACB23

Q39004366-316799AD-6274-4F33-B65B-72B683EB5E09

P2888

Q39004366-1CC4C3DA-7BC4-4DE1-998F-C8AEA1681B74

P304

Q39004366-9DDA3445-6B8C-492B-BEDF-61500A14C911

P31

Q39004366-0FFFE65F-F991-46DA-8ABA-918E6FA62246

P356

Q39004366-121DAF66-8380-4993-904C-4974A1EDCB22

P478

Q39004366-DBD689BF-5FD9-4FDD-AF65-764427CBBCA1

P50

Q39004366-9E1BAEAF-7B03-4D9B-BCB8-5EFD228B621A

P577

Q39004366-BCEC66D7-7C6D-42BA-BD4D-44BDFB8A2BFD

P5875

Q39004366-020594A2-D3D4-46C1-9A30-177D34B87BB6

P6179

Q39004366-E7FCEFAC-02F2-4843-B4E3-A7A17D4B184A

P698

Q39004366-F7BE6D82-2EB4-4D89-ABA4-60878216C9BE

P921

Q39004366-C50D670E-47A8-4A0D-869A-648255644810

P932

Q39004366-F100BF99-332E-477C-8ECF-73688CAB2D86

P356

P1433

Journal of Hematology & Oncology

P1476

A novel anti-CD19 monoclonal a ...... y against B cell malignancies.

@en

P2093

Aimable Nahimana

http://www.w3.org/2001/XMLSchema#string

Dominique Aubry

http://www.w3.org/2001/XMLSchema#string

Jonathan Back

http://www.w3.org/2001/XMLSchema#string

Julie Macoin

http://www.w3.org/2001/XMLSchema#string

Martin Bertschinger

http://www.w3.org/2001/XMLSchema#string

Michel A Duchosal

http://www.w3.org/2001/XMLSchema#string

Pierre Moretti

http://www.w3.org/2001/XMLSchema#string

Samuel Hou

http://www.w3.org/2001/XMLSchema#string

P2860

Unique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucose

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

Autophagy: from phenomenology to molecular understanding in less than a decade

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.

Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

P2888

P304

33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1756-8722-7-33

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Caroline S Breton

P577

2014-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

261732937

http://www.w3.org/2001/XMLSchema#string

P6179

1014164429

http://www.w3.org/2001/XMLSchema#string

P698

24731302

http://www.w3.org/2001/XMLSchema#string

P921

P932

4021825

http://www.w3.org/2001/XMLSchema#string